“…Our observation period ended in 2018 and we measured dual stimulant-opioid prescriptions through most of 2016. Because dual 30-day stimulant-opioid use is increasing in the United States ( Wei et al., 2018 ) and in other countries ( Ormhøj et al., 2018 ), our results may not generalize to the present rate and consequences of dual use.…”